News

Magle Group is proud to announce its sponsorship of the inaugural Vascular Embolotherapy and Nerve Interventions Targeting Inflammation and Pain (VENTI) Conference, to be held in Tokyo, Japan 7-8 November. VENTI brings together an esteemed international faculty of regional and global experts in musculoskeletal and pain interventions, highlighting the rapidly advancing field of vascular and nerve embolotherapy for inflammatory and […]

Magle Group today announces that its review of available clinical evidence for the use of EmboCept® S in Genicular Artery Embolisation (GAE) for symptomatic knee osteoarthritis demonstrates excellent efficacy and safety, including patient data originating from clinics in Germany and Italy. Based on these findings, Magle Group has commenced compiling the regulatory documentation to seek […]

Magle Group today announced that its proprietary surgical innovation, SmartPAN®, has been successfully registered in Singapore. This achievement allows the company to initiate the commercial launch of SmartPAN® in one of Asia’s leading healthcare markets. SmartPAN® is a bioindicator specifically developed to support surgeons in pancreatic surgery. The product provides enhanced visualisation during surgery, helping […]

Magle PharmaCept, part of Magle Group, is proud to announce the awarding of its Mattias Lorenz Research Award to PD Dr. med. Federico Collettini, a distinguished radiologist at Charité Universitätsmedizin Berlin, Germany in recognition of their research project with Degradable Starch Microspheres Transarterial Chemoembolization (DSM-TACE) in metastatic melanoma patients with hepatic progression on immune checkpoint […]

An inspiring gathering of the pancreatic community, sharing the latest research, updates, and critical discussions around improving care in pancreatic cancer and pancreatic surgery.Many valuable sessions shared the latest updates and results from impactful clinical trials, advancing both the healthcare community and patient outcomes.A big thank you to all the experts, surgeons, and partners who […]

Magle PharmaCept, a part of Magle Group, announces a strategic partnership with Pancreatic Cancer Europe (PCE), Pancreatic Cancer Europe is a European multi-stakeholder platform which aims at bringing together experts from all over Europe including academics, physicians, politicians, patient groups and journalists with a common interest and willingness to improve care for patients with pancreatic […]

We are excited to share the results of the recent SmartPAN post-market trial for elective pancreatic resections. The study assessed SmartPAN’s usability, safety, and its ability to detect intraoperative pancreatic leakage. Visualization of Intraoperative Pancreatic Leakage (ViP): The IDEAL Stage I First-in-human, Single-arm Clinical Pilot Trial of SmartPAN Key Insights For further details and to […]

From February 27th to March 1st, 2025 it’s all about the Pancreatic Surgery! Magle PharmaCept team will be participating at 44th Annual Meeting of The German Pancreatic Club in Heidelberg. Looking forward to meeting you at our symposium “ Progress and Challenges of Modern Pancreatic Surgery “ Read more Welcome to our booth for hands-on […]

Magle PharmaCept as a part of Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) announces the publication of the final results of the prospective HepaStar trial, a multicenter observational trial evaluating the safety and effectiveness of EmboCept® S DSM 50 µm in the treatment of unresectable hepatocellular carcinoma (HCC). Hepatocellular carcinoma (HCC) is the […]

Magle Group is proud to announce that its approved the initiation of a multi-centre clinical trial to explore the use of EmboCept® S in Genicular Artery Embolisation (GAE), a minimally-invasive procedure aimed at delivering immediate and long-term pain relief for patients suffering from osteoarthritis (OA) of the knee. This innovative treatment, performed by interventional radiologists […]